Related Experiment Videos
Enhanced soluble CD40L in patients with the metabolic syndrome: Relationship with in vivo thrombin generation
F Angelico1, C Alessandri, D Ferro
1IV Division of Internal Medicine, Department of Experimental Medicine and Pathology, University of Rome La Sapienza, Viale del Policlinico, 00161 Rome, Italy.
Insights
Patients with metabolic syndrome show higher levels of soluble CD40 ligand (sCD40L) and prothrombin fragment F (1+2), indicating increased inflammation and thrombin generation. These markers are linked to metabolic syndrome, inflammation, and thrombosis risk.
Area of Science:
- Cardiovascular Medicine
- Metabolic Disorders
- Hemostasis and Thrombosis
Background:
- Metabolic syndrome is characterized by a proinflammatory and prothrombotic state.
- Understanding the specific markers of these states is crucial for risk assessment.
Purpose of the Study:
- To evaluate soluble CD40 ligand (sCD40L) and prothrombin fragment F (1+2) levels in metabolic syndrome patients.
- To explore the relationship between these markers and the metabolic syndrome.
Main Methods:
- A cohort of 106 metabolic syndrome patients and 104 controls were studied.
- Plasma levels of sCD40L and F (1+2) were measured.
- Statistical analyses, including correlation and regression, were performed.
Main Results:
- Patients with metabolic syndrome exhibited significantly higher plasma sCD40L and F (1+2) levels compared to controls (p < 0.001).
- sCD40L and F (1+2) showed a strong positive correlation (r = 0.925, p < 0.001).
- sCD40L was independently associated with F (1+2), female sex, and waist circumference.
Conclusions:
- Metabolic syndrome is associated with elevated levels of sCD40L and F (1+2).
- These findings highlight the link between metabolic syndrome, inflammation, and the prothrombotic state.
Aims/Hypothesis:
The metabolic syndrome is associated with proinflammatory and prothrombotic states. This study was designed to assess the behaviour of soluble CD40 ligand (sCD40L) and prothrombin fragment F (1+2), a marker of thrombin generation, in patients with the metabolic syndrome.
Methods:
We investigated 106 patients with the metabolic syndrome, diagnosed according to the ATPIII report, and 104 subjects without the metabolic syndrome.
Results:
Plasma values of sCD40L and F (1+2) were higher in patients with the metabolic syndrome (4.11+/-1.64 vs 2.61+/-0.89 ng/ml and 1.54+/-0.49 vs 0.87+/-0.21 nmol/l, respectively; p < 0.001) and were significantly correlated (r = 0.925, p < 0.001). Stepwise multiple linear regression analysis showed that sCD40L was significantly associated with F (1+2), female sex and waist circumference.
Conclusions/Interpretation:
Patients with the metabolic syndrome have enhanced values of plasma sCD40L and F (1+2). The study provides further insight into the relationship between metabolic syndrome, inflammation and thrombosis.